Rates of cerebral atrophy differ in different degenerative pathologies

Jennifer L. Whitwell,1 Clifford R. Jack Jr,1 Joseph E. Parisi,2 David S. Knopman,3 Bradley F. Boeve,3 Ronald C. Petersen,3 Tanis J. Ferman,4 Dennis W. Dickson5 and Keith A. Josephs3

Departments of 1Radiology, 2Laboratory Medicine and Pathology and 3Neurology (Behavioral Neurology), Mayo Clinic Rochester, Rochester, MN and Departments of 4Psychiatry and Psychology and 5Neuroscience (Neuropathology), Mayo Clinic Jacksonville, Jacksonville, FL, USA

Correspondence to: Keith A. Josephs MST, MD, Department of Neurology, Divisions of Movement Disorders & Behavioral Neurology, Mayo Clinic, Rochester, MN 55905, USA
E-mail: josephs.keith@mayo.edu

Neurodegenerative disorders are pathologically characterized by the deposition of abnormal proteins in the brain. It is likely that future treatment trials will target the underlying protein biochemistry and it is therefore increasingly important to be able to distinguish between different pathologies during life. The aim of this study was to determine whether rates of brain atrophy differ in neurodegenerative dementias that vary by pathological diagnoses and characteristic protein biochemistry. Fifty-six autopsied subjects were identified with a clinical diagnosis of dementia and two serial head MRI. Subjects were subdivided based on pathological diagnoses into Alzheimer’s disease, dementia with Lewy bodies (DLB), mixed Alzheimer’s disease/DLB, frontotemporal lobar degeneration with ubiquitin-only-immunoreactive changes (FTLD-U), corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP). Twenty-five controls were matched by age, gender and scan interval, to the study cohort. The boundary-shift integral was used to calculate change over time in whole brain (BBSI) and ventricular volume (VBSI). All BSI results were annualized by adjusting for scan interval. The rates of whole brain atrophy and ventricular expansion were significantly increased compared to controls in the Alzheimer’s disease, mixed Alzheimer’s disease/DLB, FTLD-U, CBD and PSP groups. However, atrophy rates in the DLB group were not significantly different from control rates of atrophy. The largest rates of atrophy were observed in the CBD group which had a BBSI of 2.3% and VBSI of 16.2%. The CBD group had significantly greater rates of BBSI and VBSI than the DLB, mixed Alzheimer’s disease/DLB, Alzheimer’s disease and PSP groups, with a similar trend observed when compared to the FTLD-U group. The FTLD-U group showed the next largest rates with a BBSI of 1.7% and VBSI of 9.6% which were both significantly greater than the DLB group. There was no significant difference in the rates of atrophy between the Alzheimer’s disease, mixed Alzheimer’s disease/DLB and PSP groups, which all showed similar rates of atrophy; BBSI of 1.1, 1.3 and 1.0% and VBSI of 8.3, 7.2 and 10.9%, respectively. Rates of atrophy therefore differ according to the pathological diagnoses and underlying protein biochemistry. While rates are unlikely to be useful in differentiating Alzheimer’s disease from cases with mixed Alzheimer’s disease/DLB pathology, they demonstrate important pathophysiological differences between DLB and those with mixed Alzheimer’s disease/DLB and Alzheimer’s disease pathology, and between those with CBD and PSP pathology.

Keywords: magnetic resonance imaging; Alzheimer’s disease; dementia with Lewy bodies; frontotemporal lobar degeneration; progressive supranuclear palsy

Abbreviations: BSI = boundary shift integral; CBD = corticobasal degeneration; CDR = Clinical Dementia Rating; DLB = dementia with Lewy bodies; FTLD-U = frontotemporal lobar degeneration with ubiquitin-only-immunoreactive changes; MMSE = Mini-Mental State Examination; PiD = Pick disease; PSP = progressive supranuclear palsy


Introduction

Neurodegenerative disorders are defined pathologically by the deposition of abnormal proteins in the brain. The most common proteins are β-amyloid (Glenner and Wong, 1984), the microtubule-associated protein tau...
(Goedert et al., 2001), the synaptic vesicle protein α-synuclein (Spillantini et al., 1997), and the proteasomal protein ubiquitin (Hershko and Ciechanover, 1998). The protein TDP-43 has also recently been reported in association with ubiquitin inclusions; however, its specificity needs to be confirmed (Neumann et al., 2006). The most common neurodegenerative disorder is Alzheimer’s disease, which is characterized by the presence of β-amyloid plaques and tau-positive neurofibrillary tangles (NFT) (NIA, 1997). Dementia with Lewy bodies (DLB) is the second most common neurodegenerative dementia and is characterized by the presence of α-synuclein-positive Lewy bodies (Spillantini et al., 1997; McKeith et al., 2005). While Alzheimer’s disease and DLB account for the majority of cases of dementia over the age of 65, frontotemporal lobar degeneration (FTLD) has been shown to be as common as Alzheimer’s disease in subjects under the age of 65 years (Ratnavalli et al., 2002). The pathologies underlying FTLD are heterogeneous, however the most common variant, which accounts for almost 60% of cases of FTLD in some series (Josephs et al., 2004a), is frontotemporal lobar degeneration with ubiquitin-only-immunoreactive neuronal changes (FTLD-U). In FTLD-U ubiquitin-positive inclusions are found in the frontotemporal cortices and the dentate cell layer of the hippocampus (McKhann et al., 2001; Josephs et al., 2006c). Other pathological variants of FTLD are characterized by the presence of tau-positive inclusions. These include disorders such as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) (Dickson, 1999) and Pick disease (PiD).

It is likely that future treatment trials will target the biochemistry underlying each of these diseases and it is therefore increasingly important to be able to distinguish between these different pathologies. In fact, a phase IIa treatment trial aimed at reducing the burden of β-amyloid was recently undertaken (Gilman et al., 2005). While there is a relatively good correlation between the clinical and pathological diagnoses of Alzheimer’s disease, with 80–90% of pathologically confirmed Alzheimer’s disease accurately diagnosed during life (Galasko et al., 1994), misdiagnosis is found in both cases with Alzheimer’s disease, DLB and those with mixed Alzheimer’s disease/dLB pathology (Luis et al., 1999; McKeith et al., 2000; Merdes et al., 2003). In addition, the different pathological subtypes of FTLD do not map neatly onto the various clinical syndromes of frontotemporal dementia, making it difficult to predict pathology during life (Hodges et al., 2004; Kertesz et al., 2005; Forman et al., 2006; Josephs et al., 2006a, c). Hence, there is a need for sensitive and specific biomarkers to aid in the differentiation of these diseases.

MRI has become increasingly important in the assessment of brain atrophy in neurodegenerative diseases. The majority of studies have been cross-sectional in design assessing patterns of whole brain and regional atrophy in subjects with dementia. These studies have provided valuable information concerning patterns of atrophy in the different neurodegenerative dementias (Jack et al., 1992; Barber et al., 1999; Burton et al., 2002; Whitwell et al., 2005, 2006), but are limited both by the large degree of interindividual variability in brain morphology and by the fact that most studies assess clinically defined subjects without pathological confirmation. Longitudinal studies allow the assessment of brain changes over time in individual subjects using multiple serial MRI scans and therefore have the advantage of reducing the problem of interindividual variation. They can also provide information about the trajectory of the disease (Chan et al., 2003). Automated registration and subtraction techniques have been developed that provide quick and reproducible measurements of brain volume loss and ventricular expansion over time. One such technique is the boundary shift integral (BSI) which calculates the integral change in the brain/CSF boundary over the interior and exterior surfaces of the brain (Freeborough and Fox, 1997; Gunter et al., 2003). Rates of atrophy have been shown to be excellent biomarkers of disease progression in clinical cohorts and are already routinely being used as outcome measure in clinical trials (Jack et al., 2003; Fox et al., 2005).

The aim of this study was therefore to assess and compare the rates of whole brain atrophy and ventricular expansion in pathologically confirmed subjects with Alzheimer’s disease, DLB, FTLD-U, CBD, PSP and PiD.

**Material and methods**

**Subjects**

The neuropathology files of the Mayo Clinic were used to identify all cases that had come to autopsy and had been given a diagnosis of Alzheimer’s disease, DLB, FTLD-U, CBD, PSP or PiD and that had at least two volumetric head MRI scans of adequate quality for the BSI measurements. Cases with mixed Alzheimer’s disease and DLB were also included. The pathological criteria used to define these groups are outlined in detail later. All subjects had been studied prospectively. The medical records of all cases were reviewed by a behavioural neurologist (K.A.J.). In order to be included in the study all subjects had to fulfil strict clinical criteria: all pathologically defined Alzheimer’s disease cases had to have fulfilled clinical criteria for Alzheimer’s disease (McKann et al., 1984) at the time of scan. All pathologically defined DLB cases had to have fulfilled recent clinical criteria for DLB or Parkinson’s disease with dementia (McKeith et al., 2005) at the time of scan. The cases with mixed Alzheimer’s disease and DLB pathology had to have fulfilled criteria for either Alzheimer’s disease or DLB at the time of the scans. All FTLD-U, CBD, PSP and PiD cases must have fulfilled clinical criteria for one of the disorders considered to lie under the frontotemporal dementia spectrum. These include behavioural variant frontotemporal dementia, semantic dementia, progressive non-fluent aphasia, PSP, corticobasal syndrome (Boeve et al., 2003) or apraxia of speech (Neary et al., 1998; Josephs et al., 2006c). Cognitive ability across groups was assessed using the Mini-Mental State Examination (MMSE) (Folstein et al., 1975) and the Clinical Dementia Rating (CDR) scale (Hughes et al., 1982).
The baseline scan was selected as the first scan of adequate quality performed after each subject fulfilled criteria for the clinical diagnoses described earlier. In most cases, repeat scans were performed between 1 and 2 years later. Subjects were rejected if the scan interval was less than 6 months or greater than 4 years. All MRI scans were visually assessed (J.L.W. and C.R.J.). Scans were rejected for poor quality (such as motion artefact) or the presence of other pathologies (such as stroke, tumour or other structural lesion) that may influence either the structural analysis or clinical presentation.

A total of 133 autopsy confirmed cases with a pathological diagnosis of Alzheimer’s disease, DLB, mixed Alzheimer’s disease/DLB, FTLD-U, CBD, PSP and PiD were identified. Of these, 56 cases fulfilled the imaging inclusion criteria of having two volumetric head MRI scans: 12 Alzheimer’s disease, 9 DLB, 13 mixed Alzheimer’s disease/DLB, 12 FTLD-U, 5 CBD and 5 PSP. No cases of PiD identified had two usable head MRI. A group of 25 healthy living controls with two volumetric MRI scans were then matched by age, gender and scan interval, to the study cohort. All the healthy control subjects were initially recruited into the Mayo Clinic Alzheimer Disease Research Center (ADRC), or the Alzheimer Disease Patient Registry (ADPR), and were identified from the ADRC/ADPR database. Controls were identified as individuals who (i) were independently functioning community dwellers, (ii) did not have active neurological or psychiatric conditions, (iii) had no cognitive complaints, (iv) had a normal neurological and neurocognitive examination and (v) were not taking any psychoactive medications in doses that would affect cognition.

**Pathological assessment**

Neuropathological examinations were performed according to the recommendations of the Consortium to Establish a Registry for Alzheimer’s Disease (Mirra et al, 1991). In all cases pathological assessment and diagnosis was conducted by one of two expert neuropathologists (D.W.D. or J.E.P.). After removal, the brain was divided into right and left hemispheres. One hemisphere was fixed in 10% buffered formaldehyde for 7 to 10 days, and then sectioned. Scans were rejected for poor quality (such as motion artefact) or the presence of other pathologies (such as stroke, tumour or other structural lesion) that may influence either the structural analysis or clinical presentation.

**Pathological criteria**

**Alzheimer’s disease**

Subjects were classified as Alzheimer’s disease if on semiquantitative analysis based on the highest neuritic plaque count of the middle frontal gyrus, superior temporal gyrus, inferior parietal lobule, hippocampus and entorhinal cortex and midbrain, the subject had frequent neuritic plaques and met CERAD diagnostic criteria C for definite Alzheimer’s disease (Mirra et al, 1991). Plaque count was done with the modified Bielschowsky silver stain. In addition, the subject had to have had a Braak neurofibrillary stage of 5 or 6 (Braak and Braak, 1996) and therefore fulfill NIA-Reagan criteria for high probability Alzheimer’s disease (NIA, 1997). We excluded any subjects with Lewy bodies including amygdala only Lewy bodies (Uchikado et al, 2006).

**Dementia with Lewy bodies**

Subjects were classified as DLB if there was evidence of widespread α-synuclein positive Lewy bodies in limbic or neocortex that met published criteria for neocortical or limbic variant of dementia with Lewy bodies (McKeith et al, 2005). In addition, to be included in this category, on semiquantitative analysis of the neuritic plaque count as described earlier, the subject must have no histological evidence of probable or definite Alzheimer’s disease based on the CERAD criteria (Mirra et al, 1991), a Braak score of 1–3 (Braak and Braak, 1996), and low NIA-Reagan (NIA, 1997).

**Mixed Alzheimer’s disease/DLB**

Subjects were considered to have mixed Alzheimer’s disease/DLB if there was evidence of mixed pathologies. That is, if there were findings of neuritic plaque deposition density that met CERAD criteria C for Alzheimer’s disease, had a Braak stage 5 or 6, and a high probability of Alzheimer’s disease based on NIA-Reagan criteria as described earlier, plus findings of widespread neocortical or limbic Lewy bodies that met published criteria for neocortical or limbic variant of Lewy body disease (McKeith et al, 2005). We excluded subjects with amygdala only Lewy bodies (Uchikado et al, 2006).

**FTLD-U**

Frontotemporal lobar degeneration with ubiquitin-only-immunoreactive changes was diagnosed if there were inclusions that stained positive for ubiquitin, yet stained negative for tau, neurofilament and α-synuclein, in frontal or temporal cortex, and the hippocampus dentate granular cells without any evidence of motor neuron degeneration as previously described (FTLD-U) (Josephs et al, 2006b), and meeting established research criteria (McKahn et al, 2001). Cases with pathological evidence of motor neuron disease were excluded.

**Progressive supranuclear palsy**

Subjects were diagnosed as PSP if there was neuronal loss and gliosis, as well as characteristic tau-positive lesions including tufted astrocytes, coiled bodies and globose neurofibrillary tangles in cardinal nuclei (subthalamic nucleus, thalamic and brainstem nuclei, etc.) that met diagnostic criteria for PSP (Hauw et al, 1994).

**Corticobasal degeneration**

Subjects were given a pathological diagnosis of CBD if there was cortical neuronal loss and gliosis with balloon neurons and tau-positive lesions including astrocytic plaques, corticobasal bodies, and abundant neuropil threads that were located...
in cardinal regions that met diagnostic criteria for CBD (Dickson et al., 2002).

**Exclusion criteria**

With the exception of the mixed Alzheimer’s disease/DLB subjects, only subjects that were found to have a primary pathological diagnosis were included. Therefore subjects were excluded if in addition to the primary pathological diagnosis described earlier for each category, there were any additional findings of large cortical infarcts, diagnosis of another neurodegenerative disease or brain tumours.

**Image analysis**

All MRI studies were performed at 1.5T with a standardized imaging protocol that included a coronal $T_1$-weighted 3D volumetric spoiled gradient echo (SPGR) sequence with 124 contiguous partitions and 1.6 mm slice thickness ($22 \times 16.5$ cm$^2$ FOV, 25$^\circ$ flip angle).

Rates of change of the whole brain and ventricles were made using a software algorithm that has been developed in our lab and described in detail elsewhere (Gunter et al., 2003). Inputs for the algorithm included the baseline and repeat MR scans plus preprocessed brain and ventricular volumes. Whole brain masks were created for all baseline scans using MIDAS image analysis software (Freeborough et al., 1997). This is a semi-automated brain segmentation algorithm that performs an intensity thresholding step, and a series of erosions and dilations to remove non-brain structures. Manual editing was then performed in order to remove any non-brain structures from the segmentation. Ventricular segmentations were performed on all repeat scans for each subject using the autotrace subprogram in Analyze/AVW plus manual editing of anatomic outlines. The ventricular region included the lateral ventricles, the temporal horn of the lateral ventricles and the third ventricle. Serial scan pairs were then registered, i.e. spatially matched, using a 9 degrees of freedom (dof) rigid body registration. This algorithm combines a 6 dof rigid registration (three translations, three rotations), which matches the position and orientation of the two brain volumes, with an additional three scaling parameters to correct for drifts in gradient calibration over time. The algorithm also incorporates a correction for intensity inhomogeneity (Sled et al., 1998). Change in brain and ventricle volume was calculated automatically from each registered scan pair using the boundary shift integral (BSI) (Freeborough and Fox, 1997; Gunter et al., 2003). All BSI results were annualized by adjusting for scan interval and atrophy rates were calculated as a percentage change from the baseline volume.

A further scan quality assessment was performed after the scans had been preprocessed. All registered scan pairs were viewed side-by-side to check for consistency of acquisition over time. These assessments were performed without reference to the BSI results. Five scan pairs were thought to have inconsistencies in scan contrast, signal-to-noise or general scan quality across the two scans. Three cases were diagnosed with mixed Alzheimer’s disease and DBL and two had pure DBL. The whole brain BSI results for these five subjects were removed from the final analysis. The ventricular BSI measurements were thought to be more robust to slight quality changes over time due to the well-defined brain–CSF boundary in the ventricles. Therefore, all ventricular BSI data were analysed.

**Statistical analysis**

Statistical analyses were performed utilizing the JMP computer software (JMP Software, version 6.0.0; SAS Institute Inc, Cary, NC) with statistical significance set at $P<0.05$. Gender ratios were compared across groups using a chi-squared test and Fisher’s Exact test for cells with small numbers. Kruskal–Wallis test was used to compare age at scan, education, disease duration (defined as time from disease onset to the time of first MRI scan) and time from second MRI scan to death, MMSE, CDR sum of boxes, Braak score (Braak and Braak, 1996), CERAD, NIA–Reagan (NIA, 1997) and the BSI variables, including scan interval, whole brain and ventricular BSI, across groups. NIA–Reagan and CERAD data were converted to an ordinal scale for analysis (i.e. NIA low = 1, NIA intermediate = 2, NIA high = 3 and CERAD O = 0, A = 1, B = 2, C = 3). Because the control group was by definition cognitively normal, we excluded controls from tests of differences in cognitive scores. For analyses which were significant, post hoc testing was performed using the Mann–Whitney $U$-test. This two-stage strategy controls for type 1 errors, even without correcting the P-values for the pairwise tests through the same mechanism that is employed to control type 1 error in Fisher’s Protected Least Significant Differences approach. This mechanism means that pairwise comparisons are not deemed significant in the absence of a significant global test (Fisher, 1935; Rencher, 2002). Because the global tests were significant, type 1 error on the pairwise comparisons has been controlled without further corrections for multiple comparisons. Spearman rank correlations were used to assess the relationship between rates of atrophy and disease duration, age at scan and change over time in the MMSE and CDR. A linear regression model was used to adjust for any variables predicting the BSI.

**Results**

Demographic information for all subjects is shown in Table 1. There was no difference across the groups in age at baseline scan, years of education and gender ratios. Within the disease groups there was also no difference in the time from disease onset to baseline scan. However, there was a difference in the time from baseline scan to death. The mixed group was the furthest from death, while the DBL group was the closest to death. There was no difference in MMSE or CDR across the disease groups, although the PSP group had the largest median MMSE score and lowest CDR, while the CBD group had the smallest median MMSE score. By design, there were significant differences in median CERAD score across the disease groups, with the Alzheimer’s disease and mixed Alzheimer’s disease/DLB group showing significantly higher scores than the DBL, FTLD-U, CBD and PSP groups. Braak score was also significantly higher in the Alzheimer’s disease and mixed groups. The NIA–Reagan was low in the FTLD-U, CBD, PSP and DBL groups, but high in the Alzheimer’s disease and mixed Alzheimer’s disease/DLB groups.

All 12 patients with a pathological diagnosis of Alzheimer’s disease also had a clinical diagnosis of probable Alzheimer’s disease (McKann et al., 1984) by inclusion criteria. Similarly all nine cases of DBL had a clinical
diagnosis of probable DLB (McKeith et al., 2005); none met criteria for Parkinson’s disease dementia (McKeith et al., 2005). Nine of the 13 cases with mixed pathological features of Alzheimer’s disease/DLB had a clinical diagnosis of Alzheimer’s disease, two had a clinical diagnosis of DLB and in two cases the diagnosis was considered to be either Alzheimer’s disease or DLB. Ten of the 12 FTLD-U cases met criteria for behavioural variant frontotemporal dementia, while the other two met criteria for language variant frontotemporal dementia (Neary et al., 1998). Of the pathologically confirmed PSP cases two were given a clinical diagnosis of apraxia of speech (Josephs et al., 2006a), and one each behavioural variant frontotemporal dementia, corticobasal syndrome and probable PSP (Litvan et al., 1996). The clinical diagnoses in the five cases of pathologically confirmed CBD were apraxia of speech, corticobasal syndrome, behavioural variant frontotemporal dementia, degenerative dementia and probable PSP.

The median interval between the two MRI scans ranged from 1.2 to 2.0 years across the groups, with no significant intergroup differences observed (Table 2). The smallest interval was 6 months, while the largest was 3 years 6 months. There were significant differences in both whole-brain and ventricular atrophy rates across the groups (Table 2 and Fig. 1). The results of post hoc testing assessing differences between all groups are shown in Table 3. Rates of both whole brain and ventricular change were larger in the mixed, Alzheimer’s disease, FTLD-U, CBD and PSP groups compared to controls. There was no significant difference between the DLB group and the control group in either measure. The largest rates of atrophy were observed in the CBD group which had a rate of whole brain atrophy of 2.3% per year and ventricular expansion of 16% per year. The CBD group had significantly greater rates of whole brain BSI and ventricular BSI than the DLB, mixed Alzheimer’s disease/DLB, Alzheimer’s disease and PSP groups. There was also a trend for the rates of atrophy in the CBD group to be larger than those observed in the FTLD-U group. The FTLD-U group showed the next largest rates with a rate of whole brain atrophy of 1.7% per year and ventricular expansion of 10% per year which were significantly greater than the rates observed in the DLB group. The rate of whole brain atrophy in the FTLD-U group was also significantly greater than those observed in the mixed Alzheimer’s disease/DLB and PSP groups. There was no significant difference in the rates of atrophy between

---

**Table 1 Subject demographics**

<table>
<thead>
<tr>
<th></th>
<th>Controls (n = 25)</th>
<th>DLB (n = 9)</th>
<th>Mixed (n = 13)</th>
<th>Alzheimer’s disease (n = 12)</th>
<th>FTLD-U (n = 12)</th>
<th>PSP (n = 5)</th>
<th>CBD (n = 5)</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (male:female)</td>
<td>13:12</td>
<td>6:3</td>
<td>6:7</td>
<td>4:8</td>
<td>4:8</td>
<td>3:2</td>
<td>1:4</td>
<td>NS</td>
</tr>
<tr>
<td>Age at baseline (years)</td>
<td>76 (51, 87)</td>
<td>72 (59, 82)</td>
<td>76 (52, 86)</td>
<td>77 (52, 90)</td>
<td>72 (55, 87)</td>
<td>71 (61, 78)</td>
<td>69 (43, 71)</td>
<td>NS</td>
</tr>
<tr>
<td>Education (years)</td>
<td>14 (8, 20)</td>
<td>16 (12, 20)</td>
<td>12 (8, 20)</td>
<td>14 (8, 18)</td>
<td>15 (8, 18)</td>
<td>16 (12, 18)</td>
<td>12 (8, 16)</td>
<td>NS</td>
</tr>
<tr>
<td>Time from onset to baseline scan (years)</td>
<td>NA</td>
<td>4 (0, 5)</td>
<td>4 (0, 10)</td>
<td>4 (1, 9)</td>
<td>3 (1, 6)</td>
<td>4 (2, 5)</td>
<td>3 (1, 3)</td>
<td>NS</td>
</tr>
<tr>
<td>Time from baseline scan to death (years)</td>
<td>NA</td>
<td>3 (1, 6)</td>
<td>7 (3, 9)</td>
<td>5 (3, 6)</td>
<td>6 (1, 8)</td>
<td>4 (2, 6)</td>
<td>4 (2, 4)</td>
<td>0.0065*</td>
</tr>
<tr>
<td>MMSE at baseline</td>
<td>29 (24, 30)</td>
<td>24 (19, 29)</td>
<td>23 (13, 28)</td>
<td>24 (11, 29)</td>
<td>25 (19, 29)</td>
<td>28 (23, 30)</td>
<td>21 (15, 23)</td>
<td>NS</td>
</tr>
<tr>
<td>CDR at baseline</td>
<td>0 (0, 0)</td>
<td>5 (2, 11)</td>
<td>6 (1, 10)</td>
<td>4 (1, 17)</td>
<td>4 (1, 8)</td>
<td>1 (0.5, 5)</td>
<td>6 (2, 10)</td>
<td>NS</td>
</tr>
<tr>
<td>CERAD</td>
<td>NA</td>
<td>0 (0, 1)</td>
<td>3 (3, 3)</td>
<td>3 (3, 3)</td>
<td>0 (0, 1)</td>
<td>0 (0, 1)</td>
<td>0 (0, 1)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Braak score</td>
<td>NA</td>
<td>2 (1, 3)</td>
<td>6 (5, 6)</td>
<td>6 (5, 6)</td>
<td>1 (0, 2)</td>
<td>NA</td>
<td>NA</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>NIA Reagan</td>
<td>NA</td>
<td>L (L, L)</td>
<td>H (H, H)</td>
<td>H (H, H)</td>
<td>L (L, L)</td>
<td>L (L, L)</td>
<td>L (L, L)</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Data are shown as median (range). MMSE = Mini-Mental State Examination; CDR = Clinical Dementia Rating; NIA = National Institute of Aging; NA = not applicable; NS = not significant; L = low; H = high.

*Kruskal–Wallis test was performed across DLB, mixed, Alzheimer’s disease, FTLD-U, CBD and PSP groups.

**Table 2 Whole brain and ventricular data for all groups**

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>DLB</th>
<th>Mixed</th>
<th>Alzheimer’s disease</th>
<th>FTLD-U</th>
<th>PSP</th>
<th>CBD</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scan interval</td>
<td>1.4</td>
<td>1.3</td>
<td>1.2</td>
<td>1.4</td>
<td>1.2</td>
<td>2.0</td>
<td>1.0</td>
<td>NS</td>
</tr>
<tr>
<td>(1.0, 2.7)</td>
<td>(1.0, 2.5)</td>
<td>(0.8, 2.7)</td>
<td>(0.6, 2.6)</td>
<td>(0.5, 2.2)</td>
<td>(1.4, 3.5)</td>
<td>(0.9, 1.1)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Whole brain BSI</td>
<td>−0.3</td>
<td>−0.4</td>
<td>−1.3</td>
<td>−1.1</td>
<td>−1.7</td>
<td>−1.0</td>
<td>−2.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>(1.2, −0.8)</td>
<td>(0.7, −2.1)</td>
<td>(0.6, −2.8)</td>
<td>(0.4, −3.8)</td>
<td>(−0.9, −5.6)</td>
<td>(−0.8, −1.5)</td>
<td>(−1.9, −5.5)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
<tr>
<td>Ventricular BSI</td>
<td>3.1</td>
<td>4.8</td>
<td>7.2</td>
<td>8.3</td>
<td>9.6</td>
<td>10.9</td>
<td>16.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>(−2.8, 7.5)</td>
<td>(0.5, 12.6)</td>
<td>(5.1, 178)</td>
<td>(2.4, 16.0)</td>
<td>(8.6, 33.7)</td>
<td>(6.9, 13.4)</td>
<td>(11.2, 32.4)</td>
<td>&lt;0.0001</td>
<td></td>
</tr>
</tbody>
</table>

Data are shown as median (range). Negative rates represent a decrease in volume over time, whereas positive rates represent an increase in volume. P-values are calculated using the Kruskal–Wallis test.
the Alzheimer’s disease, mixed Alzheimer’s disease/DLB and PSP groups, which all showed rates of whole brain atrophy of ~1% per year and rates of ventricular expansion varying from 7 to 11% per year. No correlations were found between rates of whole brain atrophy or ventricular expansion and disease duration, baseline MMSE or CDR within any of the disease groups or across all disease groups. However age at baseline scan correlated with whole brain atrophy ($r = 0.3; P < 0.05$) and ventricular expansion ($r = -0.5; P < 0.0001$) across all groups. After adjusting for age at scan, pathology remained strongly associated with whole brain atrophy and ventricular expansion ($P < 0.0001$ for both), and we did not find age at scan to be a confounder or an effect modifier.

**Discussion**

We report rates of whole brain atrophy and ventricular expansion in a number of different pathologically confirmed neurodegenerative disorders characterized by the deposition of different proteins. The results demonstrate differences between the groups with the lowest rates of atrophy observed in the patients with DLB and the highest rates in the CBD and FTLD-U groups. The rates were very similar between the Alzheimer’s disease group, the group of subjects with mixed Alzheimer’s disease/DLB and the PSP group. These results therefore show that rates of cerebral atrophy do differ according to the underlying pathology and protein biochemistry.

The median rate of whole brain atrophy in the Alzheimer’s disease subjects was 1.1% per year, with a ventricular expansion of 8.3% per year. The rates of atrophy were significantly greater than in the control group. These rates are comparable with previous studies that have investigated clinical cohorts of subjects with Alzheimer’s disease (Fox and Freeborough, 1997; Gunter et al., 2003; Jack et al., 2004). These results support previous clinical studies showing that rates of atrophy are good discriminators of Alzheimer’s disease from controls, but add extra weight because this is a pathologically confirmed sample.

The DLB subjects showed a much lower rate of atrophy compared to the Alzheimer’s disease group, with rates of whole brain atrophy of only 0.4% per year and ventricular expansion of only 4.8% per year. These rates were not significantly different from the control group suggesting that very little global brain atrophy occurs over time in this group and perhaps that the deposition of $\alpha$-synuclein itself does not result in widespread neuronal loss. However, the subjects with both Alzheimer’s disease and DLB pathology had larger rates of atrophy which were similar to those observed in the Alzheimer’s disease group. Therefore, the presence of the Alzheimer’s disease-type pathological changes is likely driving the loss of brain volume in these subjects. Similarly, a previous study demonstrated that atrophy of the temporal lobe correlated with the presence of Alzheimer’s disease-type pathology in pathologically confirmed cases of DLB (Harvey et al., 1999). Although there was a large degree of overlap between the groups, rates of both whole brain and ventricular change were substantially larger in the mixed subjects than those with DLB suggesting that rates of atrophy may help differentiate these groups of subjects which are notoriously difficult to differentiate clinically. For example, a subject presenting with a clinical diagnosis of DLB with a low rate of atrophy is more likely to show pure DLB pathology, whereas a subject presenting with a clinical diagnosis of DLB and a high rate of loss is more likely to show mixed Alzheimer’s disease/DLB pathology. Interestingly, of the 13 subjects with mixed Alzheimer’s disease/DLB pathology the majority had a clinical diagnosis of Alzheimer’s disease rather than DLB. This suggests that the memory deficits characteristic of Alzheimer’s disease are the most likely presentation in cases of mixed pathology. No previous studies have assessed rates of brain atrophy on MRI in pathologically confirmed cohorts of subjects with DLB pathology, although a number of studies have cross-sectionally assessed subjects with a clinical diagnosis of DLB (Burton et al., 2002; Ballmaier...
et al., 2004; Brenneis et al., 2004; Hanyu et al., 2005; Whitwell et al., 2007) and looked at gross atrophy patterns using post-mortem brains (Cordato et al., 2000). A number of cross-sectional studies have found patterns of brain loss similar to those found in Alzheimer’s disease (Burton et al., 2000). These studies have similarly demonstrated different patterns of cerebral atrophy in pathologically confirmed FTLD-U, CBD and PSP groups suggesting that it is more informative to separate the specific pathological diagnoses. In fact, previous cross-sectional pathological and imaging studies have suggested that patterns of brain atrophy do not differ between tau-positive and tau-negative FTLD pathologies (Mann and South, 1993; Broe et al., 2003; Whitwell et al., 2004; Kril et al., 2005). However, these studies have tended to lump the different pathological subtypes of tau-positive and tau-negative FTLD. The rates of atrophy observed in this study differed across the FTLD-U, CBD and PSP groups suggesting that it is more informative to separate the specific pathological diagnoses. In fact, previous MRI studies have similarly demonstrated different patterns of cerebral atrophy in pathologically confirmed FTLD-U, CBD, PSP and Pick disease (Whitwell et al., 2005, 2006; Josephs et al., 2006c). Unfortunately we had no cases of Pick disease with two volumetric head scans, and therefore we were unable to investigate differences from FTLD-U, CBD and PSP.

The rates of whole brain atrophy and ventricular expansion were significantly greater in the CBD group compared to the PSP group even though both had clinically demented subjects. The rates of whole brain atrophy in the PSP group were 1% per year with a ventricular expansion of 11% per year which were similar to those rates observed in the Alzheimer’s disease group, and those that we have previously published (Josephs et al., 2006d). Although in earlier reports, dementia has been considered one of the discriminators against pathological confirmed PSP (Josephs and Dickson, 2003), recent studies have demonstrated that PSP can underlie a dementia presentation (Kertesz et al., 2005; Forman et al., 2006; Josephs et al., 2006a). Rates of atrophy have previously been reported in a clinically diagnosed PSP cohort without dementia (Paviour et al., 2006). Interestingly, the rates of loss between our PSP subjects and their PSP subjects were similar despite the fact that our subjects presented with a dementia syndrome as opposed to a more classic extrapyramidal presentation.

**Table 3** P-values for all intergroup comparisons of whole brain and ventricular BSI performed using the Mann–Whitney U-test

<table>
<thead>
<tr>
<th>Group</th>
<th>BSI</th>
<th>DLB</th>
<th>Mixed</th>
<th>Alzheimer’s disease</th>
<th>FTLD-U</th>
<th>PSP</th>
<th>CBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td></td>
<td></td>
<td></td>
<td>0.8</td>
<td>0.002</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.04</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.004</td>
<td>&lt;0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.006</td>
<td>0.006</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D LB Brain</td>
<td>0.07</td>
<td></td>
<td></td>
<td>0.09</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D LB Ventricle</td>
<td></td>
<td></td>
<td></td>
<td>0.05</td>
<td>0.005</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed Brain</td>
<td>0.69</td>
<td></td>
<td></td>
<td>0.04</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mixed Ventricle</td>
<td>0.72</td>
<td></td>
<td></td>
<td>0.06</td>
<td>0.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease Brain</td>
<td></td>
<td></td>
<td></td>
<td>0.06</td>
<td>0.06</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s disease Ventricle</td>
<td></td>
<td></td>
<td></td>
<td>0.09</td>
<td>0.34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTLD-U Brain</td>
<td></td>
<td></td>
<td></td>
<td>0.04</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FTLD-U Ventricle</td>
<td></td>
<td></td>
<td></td>
<td>0.92</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSP Brain</td>
<td></td>
<td></td>
<td></td>
<td>0.04</td>
<td>0.04</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSP Ventricle</td>
<td></td>
<td></td>
<td></td>
<td>0.92</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The rates of atrophy in CBD were larger than those observed in all other groups, with rates of whole brain atrophy of 2.3% per year and ventricular expansion of 16.2% per year. No previous longitudinal MRI studies have reported rates of atrophy in CBD, although cross-sectional studies have shown cortical atrophy affecting the frontal and parietal lobes in pathologically confirmed CBD (Josephs et al., 2004b, 2006c), and demonstrated greater atrophy cross-sectionally in CBD compared to PSP on MRI and pathologically (Groschel et al., 2004; Schofield et al., 2005; Boxer et al., 2006; Josephs et al., 2006c). The extent and magnitude of cortical atrophy has also been shown to be larger in subjects with CBD compared to an age, gender and severity matched group of Alzheimer’s disease subjects (Kitagaki et al., 2000). The increased rates of atrophy in CBD, along with the fact that the CBD patients performed worse on tests of clinical severity than the PSP patients, yet had a similar time from disease onset to scan, suggests that CBD is a more rapidly progressive disease. These results suggest first that rates of atrophy will be useful in the differentiation of subjects with pathological CBD from PSP. This differentiation is particularly important since the clinical syndromes associated with these diseases overlap to a large degree and misdiagnosis is common (Boeve et al., 2003). Up to 50% of subjects that are given a clinical diagnosis of CBD actually have PSP on pathology (Josephs et al., 2006c), and subjects with PSP on pathology are most often misdiagnosed as CBD clinically (Josephs and Dickson, 2003). Secondly, these results suggest that it is not just the biochemistry that determines the rates of brain atrophy, but that the distribution and lesion burden may also be important.

There was a trend for the CBD group to have a greater rate of atrophy compared to the FTLD-U group. This was observed for both whole brain atrophy and ventricular expansion, and may have reached significance if our subject groups were larger. Recently, many clinicians and scientists have recognized that CBD pathology may underlie an FTD presentation (Hodges et al., 2004; Kertesz et al., 2005; Forman et al., 2006; Josephs et al., 2006c) and that FTLD-U pathology can underlie a CBS presentation (Grimes et al., 1999; Benussi et al., 2006; Masellis et al., 2006). It is therefore important to be able to differentiate these two pathologies ante-mortem. Imaging–pathological studies with a larger number of subjects per group may reveal that rates of atrophy calculations can differentiate CBD from FTLD-U pathology.

While the rates of atrophy appear to differ across different pathologies, the role of the specific protein biochemistry is also important. Although most researchers consider one protein to be the primary protein in each of the main pathologies, in some cases there are mixed protein biochemistries. In Alzheimer’s disease, β-amyloid is considered by many researchers to be the primary protein (Hardy and Selkoe, 2002; Selkoe, 2002; Cummings, 2003), although tau-positive NFT (NIA, 1997) are also present and as important for the pathological diagnosis (NIA, 1997). In addition, while α-synuclein is considered the primary protein in DLB, the majority of cases also have diffuse β-amyloid-positive senile plaques, albeit not of the neuritic type required for a diagnosis of Alzheimer’s disease (NIA, 1997). These plaques are considered to be similar to those found in pathological aging (Dickson et al., 1989). The fact that our study has shown very low rates of brain atrophy in the subjects with DLB would suggest that neither α-synuclein nor β-amyloid causes widespread neuronal loss, although one study has shown that Lewy body density correlates with frontal atrophy in cases of DLB (Cordato et al., 2000). Yet, while the results from the DLB group suggest that the presence of β-amyloid does not result in large degrees of brain loss, it is unclear whether it is the combination of β-amyloid and tau, or only tau that drives the brain loss in Alzheimer’s disease subjects. In one study there was a correlation between levels of brain amyloid identified on 11C-PIB positron emission tomography and rates of brain atrophy in Alzheimer’s disease (Archer et al., 2006). This study may suggest a role for amyloid causing atrophy in Alzheimer’s disease. However, it is almost certain that the results were affected by the presence of tau-positive pathology, since subjects with a large amount of amyloid will also have a high density of tau-positive lesions as both NFT and the neuritic components of the Alzheimer’s disease plaques are tau-positive. A number of studies have demonstrated correlations between the presence of temporal lobe atrophy and the presence and severity of neurofibrillary tangles (Nagy et al., 1996; Jack et al., 2002), as well as cerebrospinal fluid levels of tau in Alzheimer’s disease (Hampel et al., 2005). In fact one study found a better correlation between temporal lobe volume and neurofibrillary tangle density than with the density of amyloid plaques (Nagy et al., 1996). Similarly, correlations have been demonstrated between the density of NFT and regional atrophy in PSP (Cordato et al., 2000). The distribution of pathology in PSP also correlates to the distribution of brain atrophy observed on MRI (Yagishita and Oda, 1996; Paviour et al., 2004).

The question of whether the specific protein inclusions in FTLD-U contribute directly to the pattern and degree of brain atrophy is less certain. It has been suggested that ubiquitin-positive inclusions may not play a critical role in the neurodegenerative process in FTLD-U (Kersaitis et al., 2006), and cases of FTLD-U have been reported with a high density of inclusions that have no brain atrophy at post-mortem (Josephs et al., 2006c).

The major strengths of this study are that all cases had undergone a detailed autopsy analysis and the biochemical diagnoses were made with strict criteria and not complicated by other secondary pathologies. The groups were also well-matched demographically and the clinical diagnoses were made prospectively using modern clinical criteria. However, a limitation of the study is the fact that the control subjects did not have autopsy confirmation.
Although it is possible that some of these subjects may show biochemical abnormalities on pathology it is unlikely
given the low rates of atrophy and the fact that most of the
subjects had been followed for several years and remained
clinically normal. A potential confounder to the compar-
ison of CBD and PSP is the fact that the PSP subjects had a
larger average scan interval than the subjects with CBD.
A large scan interval reduces the accuracy of a linear
approximation of the data, while any errors or noise within
the measurements are amplified over shorter intervals. It is
however difficult to predict the net affect of these factors on
our observed rates. The number of subjects in the CBD
and PSP groups was also small. However, both groups are
representative, in terms of disease onset, duration and
severity, of a larger pathological cohort that we have
previously published (Josephs et al., 2006c). In addition to
the underlying pathology and biochemistry, age at scan
does also seem to be playing a role in the rates of brain
atrophy. Further investigation of this finding is warranted.
It is possible that regional rates of atrophy may also be
useful in differentiating the different pathological groups
(Paviour et al., 2006). Future studies employing highly
deformable registration algorithms, rather than a rigid-body
registration algorithm, would enable an assessment of local
changes throughout the entire brain.

In summary, this study has demonstrated for the first
time increased rates of whole brain atrophy and ventricular
expansion in subjects with pathologically confirmed
Alzheimer’s disease, mixed Alzheimer’s disease/DLB,
FTLD-U, CBD and PSP compared to controls, yet low
rates of change in subjects with pure DLB pathology. These
rates may help differentiate the mixed Alzheimer’s disease/
DLB cases from the cases with pure DLB, although will not
help to differentiate the mixed cases from cases with
Alzheimer’s disease. Large differences were also observed
between cases with CBD and PSP pathology, with larger
rates in the CBD subjects. Therefore, rates of atrophy differ
across different pathological disorders and may prove
valuable for future disease modifying treatment trials
which will target the protein biochemistry underlying
each of these diseases.

Acknowledgements
This study was supported by the NIH Roadmap
Multidisciplinary Clinical Research Career Development
Award Grant (K12/NICHD)-HD49078, by grants P50
AG16574, U01 AG06786, R01 AG15866 and R01
AG11378 from the National Institute on Aging, Bethesda,
MD, NINDS-03-4842 from the Alzheimer’s Association, and
the generous support of the Robert H. and Clarice Smith
and Abigail Van Buren Alzheimer’s Disease Research
Program of the Mayo Foundation, USA. D.S.K. has been
a consultant to GE HealthCare, GlaxoSmithKline and
Myriad Pharmaceuticals, has served on a Data Safety
Monitoring Board for Neurochem Pharmaceuticals, and is
an investigator in a clinical trial sponsored by Elan
Pharmaceuticals. R.C.P. has been a consultant to GE
Healthcare and an investigator in a clinical trial sponsored
by Elan Pharmaceuticals. We would like to thank Vernon
Shane Pankratz, PhD and Stephen Weigand, MS, for their
statistical help and advice, and acknowledge Professor Nick
Fox at the Dementia Research Centre, London, UK, for
providing the MIDAS image analysis software.

References
Amyloid load and cerebral atrophy in Alzheimer’s disease: an 11C-PIB
Ballmaier M, O’Brien JT, Burton EJ, Thompson PM, Rex DE, Narr KL,
et al. Comparing gray matter loss profiles between dementia with
Lewy bodies and Alzheimer’s disease using cortical pattern matching:
Barber R, Ghokhale A, Scheltens P, Ballard C, McKeith IG, O’Brien JT.
Medial temporal lobe atrophy on MRI in dementia with Lewy bodies.
A novel deletion in progranulin gene is associated with FTDP-17 and
Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its
relationship to progressive supranuclear palsy and frontotemporal
Boxer AL, Geschwind MD, Belfor N, Gorno-Tempini ML, Schauer GF,
Miller BL, et al. Patterns of brain atrophy that differentiate corticobasal
degeneration syndrome from progressive supranuclear palsy.
Basal forebrain atrophy is a distinctive pattern in dementia with Lewy
Brose M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM.
Staging disease severity in pathologically confirmed cases of frontotem-
Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-
Chan D, Fox NG, Jenkins R, Scabili RI, Crum WR, Rossor MN. Rates of
global and regional cerebral atrophy in AD and frontotemporal
Change in rates of cerebral atrophy over time in early-onset Alzheimer’s
Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG. Regional
brain atrophy in progressive supranuclear palsy and Lewy body disease.
Cummins J. Toward a molecular neuropsychiatry of neurodegenerative
Dickson DW, Crystal H, Mattice LA, Kress Y, Schwagerl A,
Ksieazk-Reding H, et al. Diffuse Lewy body disease: light and
electron microscopic immunocytochemistry of senile plaques.
Dickson DW. Neuropathologic differentiation of progressive supranuclear
Dickson DW, Bergeron C, Chin SS, Duyskaerts C, Horoupian D, Ikeda K,
et al. Office of Rare Diseases neuropathologic criteria for corticobasal
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician.
Rates of atrophy differ by pathology

Brain (2007), 130, 1148–1158

II57


